Mr. George Tziras reports

CYBIN TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON NOVEMBER 13, 2025

Cybin Inc. will host a conference call and webcast at 8 a.m. ET on Thursday, Nov. 13, 2025, to provide a business update and report financial results for its second quarter ended Sept. 30, 2025.

Conference call details:

Dial-in:  800-245-3047 (U.S. toll free) or 203-518-9765 (international)

Conference ID:   CYBN1113

The archived webcast will also be available on the company's investor relations website on the events and presentations page.

About Cybin Inc.

Cybin is a breakthrough phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental health care by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The company is currently developing CYB003, a proprietary deuterated psilocin analog, in phase 3 studies for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the United States Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.